Medicine-induced Cardiac Hemodialysis on COVID-19

Sponsor

Yang I. Pachankis (Other)

Overall Status

Completed

CT.gov ID

NCT05711810

Collaborator

(none)

Enrollment

Location

Arm

Actual Duration (Days)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

Condition or Disease	Intervention/Treatment	Phase
Severe Acute Respiratory Syndrome-related Coronavirus Renal Dialysis Vaccines Myocarditis Allergic Infection Viral	Drug: Nifedipine 30 MG Diagnostic Test: Kangzhu BPCB0A-3A Behavioral: Low Mobility Drug: Enalapril Maleate 10Mg Tab Drug: Lansoprazole 30Mg Ec Cap Drug: Metoprolol Succinate Dietary Supplement: Coenzyme Q10 Dietary Supplement: d-alpha tocopherol acetate Dietary Supplement: Omega-3 Drug: Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release Drug: Superoxide Dismutase	Phase 4

Study Design

Study Type:

Interventional

Actual Enrollment :

1 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

The crossover model intervenes on the precarditis and myocarditis happenings on the patient, and evaluates the cause of the symptoms. Basic medicines are tested against the pathogens with the immune responses of the patient.The crossover model intervenes on the precarditis and myocarditis happenings on the patient, and evaluates the cause of the symptoms. Basic medicines are tested against the pathogens with the immune responses of the patient.

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks

Actual Study Start Date :

Jan 2, 2023

Actual Primary Completion Date :

Jan 10, 2023

Actual Study Completion Date :

Jan 12, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experiment Participant COVID-19 recombined vaccinated, 3 dose, no intervention. Nifedipine, oral, 30 mg per day for 2 days, active comparative. Angiotensin-converting enzyme inhibitor, oral, gradually increase to 20 mg per day at night. Beta blocker, oral, 23.75 - 95 mg per day in the morning. Proton-pump inhibitor, oral, 30 mg per day. Duloxetine hydrochloride, oral, placebo, 20 mg per day before sleep. Acetaminophen (sham comparator), oral, 250 mg four times per day for 8 days. Cefuroxime (sham comparator), oral, 100 mg twice per day for 6 days. Papaverine, oral, low-dosage in coughing pills for 4 days. Superoxide Dismutase (active comparator), oral, to be introduced. Bafilomycin A1 (active comparator), oral, 100 ug per kilogram per day, unlikely to be introduced for lack of funding.	Drug: Nifedipine 30 MG Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening. Other Names: Nifedipine Control-release Tablets Diagnostic Test: Kangzhu BPCB0A-3A The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects. Other Names: Heart Monitor Behavioral: Low Mobility The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system. Drug: Enalapril Maleate 10Mg Tab The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding. Drug: Lansoprazole 30Mg Ec Cap The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis. Drug: Metoprolol Succinate Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate. Dietary Supplement: Coenzyme Q10 200 mg per day is used for supplement with the cardiac interventions. Dietary Supplement: d-alpha tocopherol acetate The 268 mg twice per day dietary healthcare is the patient's usual daily use. Dietary Supplement: Omega-3 The 900 mg twice per day dietary healthcare is the patient's usual daily use. Drug: Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release Duloxetine hydrochloride is used for the patient's neurodiverse conditions. Other Names: Neurodiverse Drug: Superoxide Dismutase Superoxide Dismutase is used to substitute the missing of antiviral drugs.

Arm

Intervention/Treatment

Experimental: Experiment Participant

COVID-19 recombined vaccinated, 3 dose, no intervention. Nifedipine, oral, 30 mg per day for 2 days, active comparative. Angiotensin-converting enzyme inhibitor, oral, gradually increase to 20 mg per day at night. Beta blocker, oral, 23.75 - 95 mg per day in the morning. Proton-pump inhibitor, oral, 30 mg per day. Duloxetine hydrochloride, oral, placebo, 20 mg per day before sleep. Acetaminophen (sham comparator), oral, 250 mg four times per day for 8 days. Cefuroxime (sham comparator), oral, 100 mg twice per day for 6 days. Papaverine, oral, low-dosage in coughing pills for 4 days. Superoxide Dismutase (active comparator), oral, to be introduced. Bafilomycin A1 (active comparator), oral, 100 ug per kilogram per day, unlikely to be introduced for lack of funding.

Drug: Nifedipine 30 MG

Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.

Other Names:

Nifedipine Control-release Tablets

Diagnostic Test: Kangzhu BPCB0A-3A

The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.

Other Names:

Heart Monitor

Behavioral: Low Mobility

The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.

Drug: Enalapril Maleate 10Mg Tab

The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.

Drug: Lansoprazole 30Mg Ec Cap

The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.

Drug: Metoprolol Succinate

Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.

Dietary Supplement: Coenzyme Q10

200 mg per day is used for supplement with the cardiac interventions.

Dietary Supplement: d-alpha tocopherol acetate

The 268 mg twice per day dietary healthcare is the patient's usual daily use.

Dietary Supplement: Omega-3

The 900 mg twice per day dietary healthcare is the patient's usual daily use.

Drug: Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release

Duloxetine hydrochloride is used for the patient's neurodiverse conditions.

Other Names:

Neurodiverse

Drug: Superoxide Dismutase

Superoxide Dismutase is used to substitute the missing of antiviral drugs.

Outcome Measures

Primary Outcome Measures

Heart Rate [1 day]
The heart rate is monitored daily, and the primary goal is to stabilize the patient's heart rate.
Electrocardiogram [20 days]
Electrocardiogram reflects the blood pressure management on the patient's health outcome and potential risks.
Platelet Distribution [10 days]
Platelet distribution is measured to determine the viral induced blood-borne pathogen in the physiological responses of the patient.
Mean Platelet Volume [10 days]
MPV is measured to determine the risks in blood clot and internal vein scratches in the patient.
Eosinophil Absolute Number [10 days]
Eosinophil Absolute Number is measured to determine the intensities of infection in the patient.
Basophil Absolute Number [10 days]
Basophil Absolute Number is measured on the counteraction of the patient's immune system integrities against the rapid acidification of the viral infection.

Secondary Outcome Measures

Cardiac Enzymes [10 days]
Cardiac enzymes are measured to locate and eliminate the symptoms' causes, identify potential health risks, and to determine if subsidiary treatments are needed.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.

Exclusion Criteria:

healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV series
persons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)